Zacks Investment Research downgraded shares of ANIKA THERAPEUT (ANIK) from OUTPERFORM to NEUTRAL on January 31, 2013, with a target price of $12.00.
Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices that promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid, a naturally-occurring, biocompatible polymer found in the body. Due to its unique properties, hyaluronic acid plays an important role in numerous physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues and the transport of molecules to and within cells.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ANIKA THERAPEUT (ANIK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment